Biogenics Research Chamber Announces Facility Extension
The Biogenics Research Chamber is expanding its allergy research facility in San Antonio, Texas. The only large, permanent pollen exposure chamber in the United States will have increased capacity while broadening therapeutic testing capabilities.
San Antonio, Texas (PRWEB) May 09, 2013
Biogenics Research Chamber (http://www.biogenicschamber.com), a unique allergy testing facility in San Antonio, Texas, has broken ground on an extension. The 5,400 square feet will house a large allergy exposure chamber, a specialty chamber, and eye examination rooms. The chambers will utilize clean room technology with complete electrical back-up by generator. The extension will enhance capacity for simultaneous testing of large numbers of participants, while broadening therapeutic testing capabilities.
Dr. Robert Jacobs, founder and co-owner, noted that “It is amazing to think that we have outgrown our existing chambers in just three short years. We are excited to be the U.S. leaders in this area of research.”
Biogenics Research Chamber, the only large permanent pollen exposure chamber in the United States, opened in 2010 in the Medical Center of San Antonio. Projects have included pharmaceutical and vaccine trials and scientific studies elucidating the basic mechanisms and genetics of allergy. The extension, scheduled for completion in January 2014, is engineered to challenge with seasonal pollens as well as year-round allergy-provoking agents including dust mites and cat dander. The specialty chamber is designed for testing of novel agents for non-allergic eye and respiratory conditions.
About the Company:
Dr. Robert L. Jacobs, Dr. Daniel A. Ramirez and Dr. Charles P. Andrews are the owners and Principal Investigators of the Biogenics Research Chamber located in San Antonio, Texas. The facility has challenge chambers designed to conduct allergic and non-allergic exposure studies in a controlled environment that utilizes clean room technology. Proof of concept, dose-ranging, and onset of action studies are performed for pharmaceutical and vaccine trials. For companies investigating new products, the chambers offer the advantage of concentrating resources with the potential to shorten medication and vaccine development times.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/5/prweb10697751.htm